Quest Laboratories Limited is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces a variety of products, comprising ethical drugs, generic drugs, and over-the-counter drugs (OTC). These products are available in various forms, such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. The tablets include Cetirizine Hydrochloride Tablet IP 10 mg, Zinc Sulphate Dispersible Tablet IP, Diclofenac Sodium Tablet BP, and others. It offers dry syrup and suspension, such as Ferrous Sulphate & Folic Acid Syrup, Albendazole Suspension IP, Zinc Oral Solution USP, Alpha Amilase & Pepsine, Sucralfate Suspension, and others. Its ointments include Silver Sulphadiazine Cream IP, Diclofenac Diethylamino IP Gel, and Povidone Iodine Ointment USP.
QUEST LABORATORIES LTD Financial Highlights
- Revenue: QUEST LABORATORIES LTD reported revenue of ₹114.36 crore in FY26 vs ₹108.15 crore in FY25. It showed an increase of 5.74% on a yearly basis.
- Operating Profit: QUEST LABORATORIES LTD reported an operating profit of ₹18.11 crore in FY26 vs ₹18.68 crore in FY25. It showed a decrease of 3.05% on a year-on-year basis.
- Net Profit: QUEST LABORATORIES LTD reported a net profit of ₹15.02 crore in FY26 vs ₹13.57 crore in FY25. It showed an increase of 10.69% on a yearly basis.
QUEST LABORATORIES LTD Quarterly Result Highlights
- QUEST LABORATORIES LTD reported revenue of ₹31.09 crore in Mar 2026, compared with ₹31.18 crore in Dec 2025, representing a decrease of 0.29% on a quarter-on-quarter (QoQ) basis.
- QUEST LABORATORIES LTD reported an operating profit of ₹2.46 crore in Mar 2026, compared with ₹6.80 crore in Dec 2025, representing a decrease of 63.82% on a quarter-on-quarter (QoQ) basis.
- QUEST LABORATORIES LTD reported a profit of ₹2.87 crore in Mar 2026, compared with ₹4.03 crore in Dec 2025, reflecting a decrease of 28.78% on a QoQ basis.
- The earnings per share (EPS) of QUEST LABORATORIES LTD stood at ₹8.28 during Mar 2026.